Plant ID: NPO20090
Plant Latin Name: Dalbergia spruceana
Taxonomy Genus: Dalbergia
Taxonomy Family: Fabaceae
NCBI TaxonomyDB:
1353472
Plant-of-the-World-Online:
n.a.
China
DRD1; | |
TSHR; | |
BCHE; ACHE; | |
HIF1A; | |
SMN1;SMN2; | |
LMNA; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.745E-09 | 5.229E-05 | CYP1A2, CYP2C19, CYP2D6 |
BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 4.803E-09 | 5.229E-05 | BCHE, CYP1A2, CYP2D6 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 3.678E-07 | 1.335E-03 | BCHE, CYP1A2, CYP2C19, CYP2D6 |
MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 2.948E-07 | 1.335E-03 | ACHE, BCHE |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.924E-06 | 5.238E-03 | CYP1A2, CYP2C19, CYP2D6 |
BP | GO:0023052; signaling | GO:0050805; negative regulation of synaptic transmission | 5.617E-06 | 1.223E-02 | ACHE, BCHE, DRD1 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.323E-05 | 2.402E-02 | CYP1A2, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0004497; monooxygenase activity | 1.848E-05 | 2.415E-02 | CYP1A2, CYP2C19, CYP2D6 |
CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 1.940E-05 | 2.415E-02 | SMN1, SMN2 |
CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 2.292E-05 | 2.415E-02 | SMN1, SMN2 |
MF | GO:0005488; binding | GO:0020037; heme binding | 4.511E-05 | 3.508E-02 | CYP1A2, CYP2C19, CYP2D6 |
CC | GO:0044464; cell part | GO:0034719; SMN-Sm protein complex | 4.489E-05 | 3.508E-02 | SMN1, SMN2 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 6.357E-06 | 2.479E-04 | CYP2D6, CYP1A2, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.108E-04 | 2.160E-03 | CYP1A2, CYP2C19 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 7.075E-04 | 8.694E-03 | CYP2D6, CYP1A2 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.654E-03 | 1.290E-02 | CYP2D6, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.917E-04 | 8.694E-03 | CYP1A2, CYP2C19 |
09120 Genetic Information Processing | 09122 Translation | hsa03013 | RNA transport | 3.843E-03 | 2.141E-02 | SMN2, SMN1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 5.107E-03 | 2.490E-02 | DRD1, TSHR |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 9.680E-03 | 4.195E-02 | DRD1, TSHR |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 3.358E-02 | 7.068E-02 | CYP2C19 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 2.747E-03 | 1.786E-02 | CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; DRD1; |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
C00-D49: Neoplasms | Cancer | C00-C96 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; DRD1; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; DRD1; |